BONUSCAP-ZERTIFIKAT - NOVO-NORDISK B | Market Closed - BOERSE MUENCHEN 15:46:47 2024-05-31 EDT | ||
| 980.5 EUR | +0.09% |
|
| 1 month | +1.12% | ||
| 3 months | +4.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 980.5 | +0.09% |
| 24-05-30 | 979.6 | +0.10% |
| 24-05-29 | 978.6 | -.--% |
| 24-05-28 | 978.6 | -.--% |
| 24-05-27 | 978.6 | -.--% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 03:46 pm
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
UniCredit
|
| WKN | HD0CH7 |
| ISIN | DE000HD0CH78 |
| Date issued | 2023-11-01 |
| Strike | 1,000 kr |
| Maturity | 2024-12-20 (202 Days) |
| Parity | 1 : 1 |
| Emission price | 843.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 980.5 € |
|---|---|
| Lowest since issue | 822.8 € |
| Spread | 2.06 € |
| Spread % | 0.21% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- Certificat
